NVOS Earnings: Revenue, Net Loss & Full Report History

If you’ve searched “NVOS earnings,” you’ve probably landed on three different revenue figures and two different loss numbers, all supposedly for the same company. That’s not a typo problem. Novo Integrated Sciences, Inc. (NVOS) is a thinly traded OTC healthcare stock, its fiscal year doesn’t match the calendar year, and older articles rarely catch up with restated figures or the company’s reverse-split history.

This guide pulls together what NVOS has actually reported, what’s been driving the losses, and how to read the next earnings release without getting tripped up by stale numbers.

What Is NVOS?

NVOS is the ticker for Novo Integrated Sciences, a Bellevue, Washington-based healthcare company. Through its Canadian subsidiaries, it runs multidisciplinary clinics offering physiotherapy, chiropractic care, occupational therapy, eldercare, and rehabilitation services, alongside a smaller product and medical technology arm. It’s a services and product business, not a clinical-stage biotech waiting on an FDA decision, which is an important distinction when you’re trying to make sense of its earnings.

For background on the company’s structure and history, this comprehensive NVOS overview is a useful starting point before diving into the numbers.

NVOS Fiscal Year Basics

Novo’s fiscal year ends August 31, not December 31. So when a headline says “NVOS fiscal 2024 results,” it’s referring to the twelve months through August 2024, and the next full-year report doesn’t land until the following spring. Quarterly filings follow the same offset. Keep that in mind when you’re comparing NVOS earnings against calendar-year companies or trying to line up dates with a broader market earnings calendar, visit more.

NVOS Earnings History: Revenue and Net Loss by Year

A pattern worth sitting with: revenue has crept up almost every year, but the losses haven’t followed a straight line down. FY2022’s loss spike came largely from a big impairment charge, not from the core clinics losing more money. Strip that one-off out and the underlying trend is a company that’s growing top-line revenue slowly while operating expenses keep outpacing gross profit.

Breaking Down the Most Recent NVOS Earnings

Revenue: FY2024 revenue landed at $13.29 million, up 5.75% from $12.57 million the year before. The growth mostly traces back to new clinic locations and expanded rehab service volume rather than any single blockbuster contract.

Net loss: The net loss for the same period widened to $16.17 million, about 22% worse than FY2023. On a percentage-of-revenue basis, that’s a net margin sitting deep in negative territory, over -120%, which is steep even by micro-cap healthcare standards.

Gross profit: Gross profit has held in the $4.8-5.1 million range across the last few fiscal years. The real gap is on the operating expense line, where costs have consistently run well ahead of what the clinics and product sales bring in.

Cash position: Recent statistics put NVOS’s cash on hand under $1 million against several million dollars in debt, with negative free cash flow. That combination is the single most important number in any NVOS earnings report, because it’s what determines whether the company needs to raise more capital, and how much existing shareholders get diluted when it does.

Why NVOS Keeps Posting Losses Despite Revenue Growth

A few recurring factors show up in nearly every NVOS earnings release:

Operating expenses outpacing gross profit: Clinic overhead, staffing, and corporate costs have grown faster than the revenue base supporting them.

Non-cash charges: Impairments, debt discount amortization, and stock-based compensation have added significant non-cash losses in several fiscal years, on top of the operational shortfall.

Interest and debt servicing: Convertible notes and other financing arrangements carry interest costs that show up below the operating line and add to the bottom-line loss.

Dilution from capital raises: To keep the lights on, Novo has repeatedly turned to share issuance, warrants, and convertible instruments, which doesn’t directly worsen the net loss figure but does shrink what each existing share is worth.

That last point connects directly to the company’s reverse stock split history, which is worth reading alongside the earnings numbers since both are symptoms of the same underlying cash pressure.

NVOS Stock Reaction to Earnings

Because NVOS trades over the counter with thin daily volume, its stock reaction to earnings releases tends to be sharper and less predictable than a Nasdaq-listed peer’s. A single earnings-day move can run into double digits on very little volume, and the reaction sometimes has more to do with retail sentiment than with the actual numbers in the release. 

For a closer look at how the stock behaves day to day, this breakdown of NVOS stock volatility walks through the mechanics, and checking community chatter through NVOS Stocktwits sentiment can add useful context around how traders are reading a given report.

Key NVOS Financial Snapshot

How to Track the Next NVOS Earnings Report

1. Check the official filing, not a summary site first: SEC filings and the company’s own press releases carry the actual numbers; aggregator sites sometimes lag or misstate figures for thinly covered stocks like this one.
2. Confirm which fiscal quarter you’re looking at: Given the August fiscal year-end, an “NVOS Q1 earnings” headline refers to the September-through-November period, not the calendar Q1 most investors default to.
3. Watch the cash and debt figures as closely as revenue: For a company at this stage, the balance sheet tells you more about near-term risk than the income statement does.
4. Cross-check the reaction against broader OTC context: A wider read on where the stock stands heading into a report helps put any single earnings-day move in perspective.

Is NVOS Earnings Growth Enough to Offset the Losses?

Not yet, based on what’s been reported so far. Revenue has grown in the mid-single digits most years, but losses have grown faster in percentage terms, and the company has repeatedly needed outside capital to keep operating. 

None of that rules out a turnaround if Novo manages to control costs or scale its healthcare services segment, but the earnings trend to date shows a business that hasn’t found operating leverage yet. This isn’t investment advice, and the volatility in a stock like NVOS means outcomes can shift quickly with a single filing.

FAQs

When does NVOS report earnings? 

Novo Integrated Sciences’ fiscal year ends August 31, so its full-year results are typically reported in the following spring, with quarterly updates in between. Exact dates vary year to year, so it’s worth checking the company’s investor relations page or a recent SEC filing directly.

What was NVOS’s most recent annual revenue? 

For fiscal year 2024 (ended August 31, 2024), Novo Integrated Sciences reported revenue of $13.29 million, up 5.75% from $12.57 million in fiscal 2023.

Why does NVOS keep losing money even as revenue grows? 

Operating expenses, non-cash impairment charges, and interest on debt have consistently outpaced gross profit, pushing the net loss higher even in years when revenue increased.

Is NVOS still on Nasdaq? 

No. Novo Integrated Sciences received a Nasdaq delisting determination in 2024 after failing to maintain the minimum bid price requirement, and its shares now trade over the counter.

Does NVOS earnings data affect the stock price much? 

Yes, often more sharply than for larger companies, because thin trading volume on OTC Markets means even a modest reaction to an earnings release can move the price by a wide margin in a single session.

Conclusion

NVOS earnings tell a consistent story: modest, steady revenue growth from the clinic and product business, offset by losses that have grown just as fast, if not faster. The company isn’t burning cash on a single failed bet, it’s dealing with the slower grind of operating expenses and financing costs outrunning gross profit year after year. 

Before acting on any headline number, check the original filing, confirm which fiscal period it covers, and look at the cash position alongside the revenue line. That combination tells you far more about where NVOS stands than any single earnings figure in isolation.